and because of the ability of the human glial progenitors to expand for several months. Unlike primary astrocyte cultures, the human stem cell-differentiated astrocytes do not contain immune cells, such as microglia, which confounds experimental settings through activation of astrocytes. In contrast to serum-containing medium, our protocol allows growth and differentiation of human astrocytes under chemically defined medium. More importantly, the present protocol describes the procedure for generating astrocytes with specific regional and functional characteristics. Because of the human origin of the cells, the potential disadvantage of the protocol is the length of the long-term culture for obtaining mature astrocytes as compared with primary cultures. However, this shortcoming is readily overcome by the simplicity of the culture system and the long-term expandability of the progenitors. This protocol should also allow generation of astrocytes from human iPSCs with specific pathological traits.
Experimental design
The astrocyte differentiation procedure encompasses three major stages (Fig. 1) . The PSCs are first converted into multipotent neuroepithelial cells with the ability to be regionally specified, otherwise known as neural stem cells, in the first 3 weeks (this is discussed in detail in references 19 and 20) ; this is followed by transition of the neuroepithelia to astroglial progenitors in the next 2 months, and, finally, by the generation of immature astrocytes after long-term expansion and differentiation for 1 week. The entire process, except for the first 4 d of the transition period, involves the use of a simple neural medium (NM) with different additives at specific stages. In each of the stages, cell identity is determined by morphology and expression of cell type-specific markers. Astrocyte identity may be further ascertained by their functional attributes, such as their high rate of glutamate uptake and their ability to promote maturation of cocultured neurons 17 . In the first stage, human PSC-derived neuroepithelial cells with the ability to be regionally patterned may be generated or obtained through various means, either by differentiation of PSCs cocultured with mouse embryonic fibroblasts [19] [20] [21] ( Fig. 2) , differentiation of PSCs in feeder-free conditions 22 , or from commercially available sources. Under an adherent culture mode, neuroepithelial differentiation can be readily confirmed by the appearance of columnar epithelia that organize into neural tube-like rosettes at days 10-15 of differentiation (Fig. 2c) . The non-neural colonies, indicated by lack of the typical rosettes (Fig. 2d) , can be easily removed, thus enriching the neural population.
It is during the neuroepithelial differentiation period from days 8 to 15 in which cells can be readily patterned to regional progenitors for generating diverse types of neurons. We recently discovered that it is during the same progenitor period that astrocyte subtypes are specified 17 . Therefore, application of morphogens at this period will allow generation of different classes of astrocytes, in the same manner as generating neuronal subtypes. For example, addition of sonic hedgehog will permit generation of astrocytes with ventral forebrain phenotypes, while those generated without addition of morphogens exhibit cerebral cortical characteristics. Astrocytes generated from retinoic acid-patterned progenitors exhibit spinal cord phenotypes. This protocol is designed to allow generation of astrocytes with versatile and specific phenotypes.
In the second phase, the floating neural progenitor aggregates are expanded in suspension culture with epidermal growth factor (EGF) and fibroblast growth factor-2 (FGF2), mitogenic factors commonly used for propagating neurosphere cultures 23 . As the human neuroepithelial cells give rise to predominantly neurons in the following month before gliogenesis, the progenitor spheres are mechanically triturated weekly to reduce the neurogenic potential and to expand the gliogenic progenitors in the presence of the mitogens, a modification of a protocol for expansion of human fetal-derived neurospheres 24 . By about day 90, the vast majority of the progenitors can be identified by immunodetection with antibodies against S100β and CD44, both of which are expressed in astroglial progenitors and astrocytes, thus the floating aggregates are referred to as 'astrospheres' . These glial progenitors may be expanded for additional months as astrospheres or as sphere-reforming monolayers (Fig. 2e,g,i) .
Finally, in the third stage, the astroglial progenitors are differentiated into functional astrocytes by removal of mitogens, which will cause cells to exit the cell cycle. Ciliary neurotrophic factor (CNTF) is added for 6 d to activate gliogenic gene expression, although CNTF is not necessary to induce GFAP expression at later time periods. The astrocyte identity is ascertained by the expression of S100β and later GFAP (Fig. 3) , with largely absence of neurons. If cells have been regionally patterned at the neuroepithelial stage, these will carry distinctive markers, such as Hoxb4 for posterior identity, or Nkx2.1 for ventral identity 17 , although expression of Nkx2.1 decreases over time. Functional properties of the in vitro-produced human astrocytes may be verified by their electrophysiological properties (absent or minimal sodium currents, no action potentials, glutamate-induced currents), glutamate uptake, calcium wave networks and their ability to maintain the astrocytic phenotype after transplantation into a mouse central nervous system. In addition, astrocyte monolayers or conditioned medium can support neuronal maturation. Fig. 2a,b) . Paraformaldehyde (4%, wt/vol) Dissolve 220 mg of sodium phosphate monobasic and 1.22 g of sodium phosphate dibasic into 50 ml of water. In a fume hood, add 4 g of PFA in 50 ml of 60 °C water while stirring. Add 2-3 drops of 2N NaOH to dissolve. Combine the two solutions and cool to 22 °C. Adjust pH to 7.4 with HCl, filter with a Steriflip, and store at 4 °C for up to 2 weeks. ! cautIon PFA is very hazardous in case of skin contact, eye contact, ingestion and inhalation, leading to irritation. Overexposure can lead to death. Polyornithine (1 mg ml − 1 ) Dissolve 100 mg of PLO into 100 ml of boric acid buffer, pH 8.4. Filter with a Steriflip and store at − 20 °C for up to 3 months. PSC medium (500 ml) Combine 390 ml of D-MEM/F-12, 100 ml of KOSR, 5 ml of NEAA, 5 ml of 100× GlutaMAX, and 3.6 µl of 2-mercaptoethanol. Store at 4 °C up to 2 weeks. ! cautIon 2-Mercaptoethanol is combustible and very hazardous in case of contact with skin, contact with eyes, ingestion and inhalation. Overexposure can result in death. Wear protective clothing, avoid contact and keep away from sources of ignition. Retinoic acid (100 mM, 1 mM) Dissolve 30 mg of RA into 1 ml of DMSO for a 100 mM solution. Aliquot and store at − 20 °C. Before use, dilute 50 µl into 5 ml of ethanol for a 1 mM solution and store at − 20° C for up to 2 weeks.  crItIcal Keep RA protected from light, as it is light sensitive. Sonic hedgehog (100 mg ml − 1 ) Dissolve 25 µg of SHH into 250 µl of sterile D-PBS for a 100 µg ml − 1 stock. Aliquot as needed and store at − 80 °C for up to 3 months. It is stable for 1 month at 4 °C. EQUIPMENT SETUP Cell culture incubation conditions Set the incubator at 37 °C and connect to a CO 2 tank for a final concentration of 5%. Add water for humid conditions. PLO-and laminin-coated cover slips Acid-etch the cover slips by overnight shaking in concentrated nitric acid, followed by eight washes with distilled water over a period of 24 h. Insert acid-etched cover slips into each well of a 24-well plate in sterile conditions, add 0.5 ml of ethanol to each well to sterilize, and after the ethanol evaporates wash two times with sterile water. Dilute the PLO stock solution 1:10 into sterile water. Add 75 µl of diluted PLO onto each cover slip and store in an incubator overnight. Remove PLO and dry 30 min, followed by three water washes. Dry again and store at − 20 °C up to 1 month. One hour before use, dilute 25 µl of laminin solution into 1.25 ml of NM and add 50 µl onto each of the PLO-treated cover slips. Do not let the solution spread off the cover slip onto the edge of the well. Store in an incubator for at least 1 h before plating cells. (Fig. 2c) . If cells are in a single layer or dark clusters of dead cells appear (Fig. 2d) , the clusters should be mechanically removed and dispensed. Feed the culture with fresh medium every 2-3 d with exchange of half of the medium.
2|
Without the addition of morphogens, human PSC-derived neural cells will have dorsal telencephalic characteristics 25 . (Optional) If astrocytes of different regional identities are needed, add morphogens starting at the early stage of neuroepithelial cell differentiation (day 10 from the beginning of PSC differentiation). RA (1:2,000 dilution for 0.5 µM) or SHH (1:1,000-1:200 dilution for 100-500 ng ml − 1 ) may be added to NM to caudalize or ventralize the progenitor cells, respectively, or a combination of both will generate caudal/ventral cells. These molecules should be continuously present in the NM until day 21 for complete patterning.
3|
At day 15, a time point when multiple rosette formations are present throughout the neuroepithelial cell culture, lift attached clusters. Typically, 3-10 clearly distinguishable rosettes are observed within one neuroepithelial cell colony and the numbers vary between clusters. Note that non-neural colonies with an absence of rosette formation should be mechanically removed before lifting the neural colonies to avoid contamination with non-neural cells. To lift, exert a force upon the clusters with a 1-ml pipette until they detach without breaking excessively into single cells. Flat, non-neural cells that migrate on the outer edge of the colonies should remain attached to the plate because of their higher degree of attachment.  crItIcal step For maximum cell survival, minimize breaking up the neural colonies at this stage.
4|
Transfer floating aggregates to a 15-ml conical tube and centrifuge for 2 min at 100g, a speed used for all subsequent steps. Remove old medium (supernatant) by vacuum and resuspend the aggregates with prewarmed NM. Typically, from one 6-well plate of neuroepithelial cells, resuspend into 24 ml of NM. If morphogens are to be added to the culture system, dilute into NM before use.
5|
Use a pipette to transfer 8 ml of resuspended aggregates into each of three T25 flasks. Different-sized flasks may be used if desired.  crItIcal step The neuroepithelial aggregates tend to stick on the inside of the pipette, which results in a decreased yield. Therefore, rinse the pipette with medium before transferring the aggregates to avoid losing spheres. Morphogens are no longer necessary at this late stage for regional patterning. As described above, 75% of the medium should be replaced every 2-3 d and spheres tightly attached to the flask should be discarded during the exchange of new flasks.
6|

8|
During days 21-90, break any large spheres into multiple smaller clusters. To break spheres, take large spheres into a flamed, curved Pasteur pipette that has been rinsed with medium at least three times to avoid attachment of spheres to the wall of the pipette. Then force the spheres out once or twice. A detailed procedure for making these pipettes has been described elsewhere 21 .  crItIcal step Care should be taken to flame-polish the Pasteur pipette to smooth edges and create an appropriate aperture (0.2-0.5 mm in diameter), as a more narrow opening will cause excessive damage and cell death.
9|
Between days 21 and 90, the EGF/FGF2-expanded and regularly triturated progenitor clusters will switch from neurogenic to gliogenic, and these aggregates are referred to as astrospheres. At day 90, verify the efficiency of gliogenesis by immunostaining. Expected outcome at this time period is that ~80% of cells are S100β + , ~80% are CD44 + and ~10% are 12| Resuspend cells at a concentration of at least 100,000 cells per ml and transfer to new T25 flasks to allow cells to attach. Astroglial progenitors will not proliferate well at a lower density. Astroglial progenitors tend to cluster together in the next few days, forming aggregates that will eventually detach and again generate free-floating astrospheres (Fig. 2e,g,i) . If rapidly dividing fibroblast-like cells are observed (Fig. 2f,h ), they produce a confluent layer without reforming spheres. Such a culture is likely to contain non-neural or neural crest derivatives and will not generate astrocytes efficiently.
13|
Expand the astrospheres for at least 6-8 months in total, thus generating large quantities of astrocytes. The expansion rate usually slows down after 6 months of culture. The maturation state of the astroglial progenitors in the astrospheres differs depending on the time of expansion. When measured at day 90, ~80% of cells will become S100β + and ~10% are GFAP + after removal of mitogens (Fig. 3) . The S100β + /GFAP − cells are likely to be immature or nonreactive progenitors, as this population decreases with time. When the astrospheres after day 120 are differentiated after removal of mitogens, nearly all the cells are positive for S100β and >90% of them are S100β/GFAP + within a week; also, no neurons are present (Fig. 3) . In addition, further quality control measures as described for day 90 (Step 9, option B) may be taken to confirm lack of contaminating neuroepithelial cells, neurons and oligodendrocytes with immunocytochemical detection of markers, such as Pax6, β-III tubulin and 04, respectively (Fig. 1) . ? trouBlesHootInG ? trouBlesHootInG Troubleshooting advice can be found in table 2.
• tIMInG Steps 1-6, Regional specification of neuroepithelial cells (optional) and formation of free-floating aggregates: 11 d Steps 7-9, Induction of gliogenesis: 69 d Steps 10-13, Astrosphere maintenance and maturation: 30 + d
antIcIpateD results
This protocol makes use of developmental principles for stepwise differentiation of Pax6 + neuroepithelial cells from human PSCs 19 , which later bypass neuronal differentiation to develop into astroglial progenitor cells by expanding the progenitors with mitogens and by reducing cell-to-cell contact, and then finally become mature functional astrocytes. These astrocytes will, by default, display dorsal telencephalic properties, unless instructed otherwise, by addition of morphogens during the neuroepithelial stage. The majority of astroglial progenitors express S100β and CD44 and they can differentiate into GFAPexpressing maturing astrocytes (Fig. 3) . Efficient neural induction is critical for this protocol because unwanted non-neural cells will quickly proliferate and eventually overtake the culture (Fig. 2f,h ). In the final stage, CNTF is applied during Increase plating density to >100,000 cells per ml, dissociate more gently terminal differentiation, as it is known to induce maturation through the Janus kinase signaling pathway, though it may be optional to generate functional distinct astrocytes through activation of alternate pathways, such as through bone morphogenetic protein signaling 26, 27 . The timeline of each stage reported here, though very reproducible with human ESC lines, may have discrepancies with the timing of human iPSC differentiation because of variations of neuroepithelial cell differentiation between lines 15 . Differentiation of disease-specific iPSC lines with genetic variations of astroglial regulatory factors may also lead to differences, which would be advantageous for studying human disease mechanisms. Regardless, with efficient neural induction and subsequent proliferation of astroglial progenitors, a large number of astroglia at similar stages of development can be generated in a simplified manner. The temporal expression of astrocyte markers during differentiation of PSCs recapitulates the timing of human development 28, 29 , highlighting its advantages as a model system for development. This protocol may be combined with other methods, e.g., sorting of CD44-expressing astroglial progenitors after the second month of differentiation, if desired.
Astrocytes generated using this protocol will have functional-and regional-specific attributes, allowing a new system to study developmental processes of astrocytes, disease-related mechanisms and possible therapeutic discovery. To study the functions of these astrocytes in an in vivo system, PSC-derived astrocytes may be transplanted into a normal or diseased nervous system at different stages of development. By applying specific sets of morphogens at days 10-21 of this protocol, many more diverse subtypes of astrocytes may be generated 17 .
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